Cytokine storms force Mirna to shutter a trial; Artios gathers $33M for cancer drug work
A series of severe cases of cytokine release syndrome forced Austin, TX-based Mirna Therapeutics to shut down a Phase I study of its lead microRNA drug, MRX34. Mirna also opted not to start another study until it can analyze the situation. Their shares $MIRN cratered in the news, dropping 23%. “We made the difficult decision to close the study after a fifth, immune-related serious adverse event was recently reported by one of our clinical sites,” noted CEO Paul Lammers. “This patient experienced severe (Grade 4) cytokine release syndrome and is undergoing treatment. We have notified the U.S. FDA and the Korean FDA of our decision and are in the process of closing the trial.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.